Alterity therapeutics limitedATHE.US Overview

US StockHealthcare

(No presentation for ATHE)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ATHE Overall Performance

ATHE AI Analysis & Strategy

ATHE Recent Performance

0.41%

Alterity therapeutics limited

0.81%

Avg of Sector

-1.14%

S&P500

ATHE PowerScanner

ATHE Key Information

ATHE Valuation Metrics

ATHE Earnings Table

ATHE Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.